Dr. Richard Furman Discusses the Approval of Ibrutinib for the Treatment of Patients with Waldenstrom’s Macroglobulinemia

In this Onc Live video, Dr. Richard Furman, Director of the CLL Research Center discusses the findings of a recent study that led to the approval of ibrutinib as a mono-therapy for patients with Waldenstrom’s Macroglobulinemia.

A full listing of open clinical trials for Waldenstrom’s Macroglobulinemia can be found here.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s